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Background: Australian Aboriginal and Torres Strait Islander peoples (Indigenous Australians) smoke at much
higher rates than non-Indigenous people and smoking is an important contributor to increased disease, hospital
admissions and deaths in Indigenous Australian populations. Smoking cessation programs in Australia have not had
the same impact on Indigenous smokers as on non-Indigenous smokers. This paper describes the outcome of a
study that aimed to test the efficacy of a locally-tailored, intensive, multidimensional smoking cessation program.
Methods: A randomised controlled trial of Aboriginal researcher delivered tailored smoking cessation counselling
during face-to-face visits, aiming for weekly for the first four weeks, monthly to six months and two monthly to
12 months. The control (“usual care”) group received routine care relating to smoking cessation at their local
primary health care service. Data collection occurred at enrolment, six and 12 months. The primary outcome
was self-reported smoking cessation with urinary cotinine confirmation at final follow-up (median 13 (interquartile
range 12–15) months after enrolment).
Results: Participants in the intervention (n = 55) and usual care (n = 108) groups were similar in baseline
characteristics, except the intervention group was slightly older. At final follow-up the smoking cessation rate for
participants assigned to the intervention group (n = 6; 11%), while not statistically significant, was double that of
usual care (n = 5; 5%; p = 0.131). A meta-analysis of these findings and a similarly underpowered but comparable
study of pregnant Indigenous Australian women showed that Indigenous Australian participants assigned to the
intervention groups were 2.4 times (95% CI, 1.01-5.5) as likely to quit as participants assigned to usual care.
Conclusions: Culturally appropriate, multi-dimensional Indigenous quit smoking programs can be successfully
implemented in remote primary health care. Intensive one-on-one interventions with substantial involvement
from Aboriginal and Torres Strait Islander workers are likely to be effective in these settings.
Trial registration: Australian New Zealand Clinical Trials Registry (ACTRN12608000604303).
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In 2008, the age-standardised prevalence of current
smoking among Indigenous people was more than
double that among other Australians (49.8% compared
with 20.5% of those aged 18 years and over) [1]. Much
of the health disparity between Indigenous and non-
Indigenous Australians is attributable to conditions that
are either due to or exacerbated by tobacco smoking.
Ischaemic heart disease and type 2 diabetes contributes
14% and 12%, respectively, to the Indigenous health gap
[2]. Indigenous men and women 35 – 54 years of age die
from ischaemic heart disease at 7.2 and 16.6 times,
respectively, the rate in the non-Indigenous Australian
population [3]. In addition similarly aged Indigenous
men and women die from chronic lung disease at a rate
9.7 and 13.9 times greater respectively, and from lung
cancer at a rate twice that of non-Indigenous Australians
[3]. Smoking substantially increases the risk of both
macrovascular and microvascular complications of dia-
betes and may have a role in the development of type 2
diabetes [4]. Stopping smoking has been described as
the single most important individual change Indigenous
Australian smokers could make to improve their health.
While many smokers quit unassisted, for others help-
ing them to become and remain non-smokers is difficult.
Randomised controlled trials (RCTs) aimed at the gen-
eral smoking population demonstrate interventions with
success rate of at most 25% at 12 months and more
typically substantially lower. In the general population
smoking cessation interventions have an odds ratio (OR)
of between 1.42 and 2.17, depending on the type of
intervention used [5]. There have been several smoking
cessation interventions conducted amongst disadvan-
taged and Indigenous groups [6,7]. However, there is a
paucity of published RCTs [7].
Smoking cessation programs are a major priority in
Indigenous Australian health. A range of strategies have
been used to encourage Indigenous Australians to quit
smoking however there have been few good quality stud-
ies that show which approaches work best. The only
published Indigenous smoking cessation RCT investigat-
ing the benefit of a personal support intervention with
validated smoking cessation showed a doubling of the
smoking cessation rate after providing extra support
(7% v 3%), although this improvement was not statisti-
cally significant [8].
While smoking cessation rates in primary health care
settings are likely to be lower than in settings where
patients have specifically sought help, particularly when
health care providers approach patients to quit [8,9],
more evidence of effective strategies are needed if
effective policy is to be developed and implemented. Abo-
riginal Community Controlled Health Services (ACCHS)
provide an appropriate setting for such interventions asthey provide a culturally safe environment that has been
shown to be successful in delivering interventions in other
health care areas [10-12].
The Be Our Ally Beat Smoking (BOABS) Study aimed
to test the efficacy of a culturally appropriate multidi-
mensional intensive smoking cessation intervention pro-
vided by Aboriginal researchers in helping Aboriginal
and Torres Strait Islander people to become and remain
non-smokers at 12 months.
Hypothesis
A culturally appropriate, multidimensional, intensive
smoking cessation intervention, provided by trained
Aboriginal researchers, will be more effective than
current standard practice in achieving and sustaining
cessation to tobacco consumption among Australian
Aboriginal and Torres Strait Islander peoples.
Methods
Project staff
The project was undertaken at two ACCHS located in
the remote towns of Derby (Derby Aboriginal Health
Service – DAHS) and Kununurra (Ord Valley Aboriginal
Health Service – OVAHS) in the Kimberley region of far
north Western Australia [13] between January 2009 and
June 2012. Aboriginal researchers were trained to deliver
the program. These researchers came from various back-
grounds: Aboriginal Health Worker (1), other Aboriginal
health service employees (4) and people without a health
background (4). For most of the study project managers
were based at the centralised coordinating site (Kimberley
Aboriginal Medical Services Council), in Broome. Investi-
gators and research staff met before and at least annually
during the trial to discuss all procedures. The Broome-
based investigators (JM, DA, CN) met regularly to discuss
any problems that arose during the trial.
Study design and participants
The protocol for the BOABS Study has previously been
described [13]. Briefly this study was a prospective,
randomised, trial with parallel groups. Aboriginal and
Torres Strait Islander smokers (current or who had quit
within two weeks of enrolling) aged 16 years or older
who were residents of Derby and Kununurra and who
demonstrated any desire to quit smoking or cut down
on the amount of cigarettes they smoked were recruited
to the study. The exclusion criteria were: unable to pro-
vide informed consent; a health condition that would
prevent them from completing the trial; or unlikely to
be available for follow up at 12 months.
Recruitment strategies
Participants were actively and opportunistically recruited. Ac-
tive recruitment was facilitated by the Aboriginal researchers
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and community links. Participants were passively re-
cruited through DAHS and OVAHS routine clinic visits as
well as through running dedicated chronic disease pre-
vention and screening clinics. Clients known or found to
be current smokers were offered participation in the trial
by health care providers. Recruitment originally intended
to last 12 months eventually concluded at 30 months due
to resource constraints (see below).
Randomising and masking
As the planned intervention was labour intensive, partic-
ipants were allocated to usual care or intervention
groups in a 2:1 ratio. A computer generated random
allocation sequence was used. Sealed envelopes contain-
ing the allocation were kept at the centralised coor-
dinating site. Allocation occurred via telephone with
envelopes being opened in sequential order for each site
only when a participant had provided written consent
and been enrolled in the study, eligibility confirmed, an
identification number assigned, and the first questionnaire
completed.
Due to the nature of the intervention the participants
and research team were subsequently aware whether the
participant belonged to the usual care or intervention
group. Local healthcare staff may have been aware of
this. The staff performing the urinary cotinine assay
were blinded to the allocation.
Procedures
Participants allocated to usual care received routine care
relating to smoking cessation at their local primary
health care service, including advice regarding quitting,
pharmacotherapy, and self-initiated follow up. Partici-
pants allocated to the intervention group received usual
care as above. In addition they were provided with
smoking cessation counselling at face-to-face visits,
which were scheduled weekly for the first four weeks,
monthly to six months and two monthly to 12 months
(12 sessions). The content delivered by Aboriginal re-
searchers to participants in the intervention group inclu-
ded: motivational interviewing; diversions and strategies to
deal with smoking triggers; action plans for preventing and
dealing with short term relapses; discussion regarding the
positives of smoking cessation; referral for and titration of
pharmacotherapy; identification of factors driving smoking
and case management to address these by linking par-
ticipants with additional non-health support agencies
(e.g. public housing, welfare, domestic violence and
alcohol services); and strategies for smoking cessation-
associated weight gain. They were also encouraged to
attend a monthly smoking cessation peer support group.
We planned that the Aboriginal researchers would
organise weekly case conferences with the health careclinic medical officer/general practitioner to review all
active participants in the intervention group.
Study endpoints
Planned study endpoints were at six and 12 months
following enrolment. The planned primary endpoint was
not smoking at 12 months defined as self-reported non-
smoking for at least seven days [8] and low urinary
cotinine [14]. Final follow-up was extended to improve
completeness, with 22 and 11 follow-ups from the usual
care and intervention groups, respectively, occurring
more than 15 months after enrolment. Multiple ques-
tions (Are you still a smoker? Have you smoked since
the last BOABS Smoking Checkup? When was your last
cigarette? On an average day how many cigarettes a day
do you smoke?) were used to assess self-reported quit-
ting. Urinary cotinine was analysed using tandem mass
spectrometry (Waters 2795 Autosampler with Waters
Quattro Premier Mass Spectrometer, Milford, MA USA)
with a cut-off to indicate not smoking of < 50 ng/mL
[15]. Secondary outcomes were the proportion of partici-
pants who: were not smoking at six months for at least
seven days as determined by self-report; reported fair/
poor health using a self-reported health questionnaire
[16]; reported 20% or greater reduction in the number of
cigarettes smoked each week; and various process evalu-
ation indicators that assessed how well the intervention
program was implemented according to the protocol
(e.g. number of ‘face-to-face’ meetings completed). We
also recorded quit attempts during the study.
Sample size
The sample size estimation was based on a two-sided
alpha of 0.05, power of 80%, ratio of intervention to
control participants of 1:2, and an anticipated efficacy of
maintaining smoking cessation at 12 months of 3% in
the control group based on local program evaluation
(personal communication CN) and 13% in the interven-
tion group. Based on these assumptions the sample size
required was 106 in the intervention group and 212 in
the control group. To take into account those lost to
follow up, the target sample size was 120 in the inter-
vention group and 240 in the control group.
Statistical analysis
Differences in baseline characteristics, and primary
and secondary outcomes were compared using χ2
tests for categorical data, t tests for continuous
normally distributed data and Mann–Whitney test for
continuous non-parametric data. Changes from baseline
to final follow-up of nicotine dependency score ≤5
(decreased dependency, no change, increased dependency)
were compared using the Cochran-Maentel-Haenzel test
for linear association. Fishers exact test and relative risks
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between the intervention and control groups. Multivariate
analyses did not significantly change the results and hence
have not been included. All statistical tests were two-sided
and a p value less than 0.05 was taken to be statistically
significant.
Systematic review and meta-analysis
Based on CONSORT recommendations of placing the
results of this study into context [17] we carried out,
post hoc, an associated systematic review of smoking
cessation trials in Indigenous populations. Our selection
criteria for inclusion in the meta-analysis were rando-
mised controlled trials of interventions with validated
smoking cessation in Indigenous populations. Our exclu-
sion criteria were 1) trials comparing pharmaceutical
interventions compared with placebo and 2) all studies
where quitting smoking was not biochemically validated
for all participants who self-reported they had quit
smoking (e.g. urinary cotinine). A recent meta-analysis
of four studies reported a RR of 1.43 (95% CI; 1.03-1.98)
for smoking abstinence at 6–12 month follow-up in the
intervention group, based on a very low quality of
evidence [6]. Additional searches of the Cochrane
Tobacco Addiction Group Specialised Register of Trials
(June 2013), MEDLINE (June 2013), online clinical trial
databases and publication references for potential stud-
ies were also conducted. The four trials reported in the
recent review did not meet the selection criteria: two
were not randomised [18,19], one assessed the efficacy
of a pharmaceutical intervention (bupropion) compared
with placebo [20], and one had smoking cessation
validated in only a subset of participants who self-
reported that they had quit smoking [21].
Only one published study [8] met these criteria and
we combined our results with the data from this RCT.
Although this study focused on pregnant women, like
our study this was based on one-on-one intensive sup-
port compared with usual care. Both studies also allowed
recent quitters to enrol and in line with other smoking
cessation studies used 7-day point prevalence abstinence
of smoking confirmed by cotinine to classify non-
smokers [22]. An estimated pooled weight average for
RRs was calculated using the Mantel-Hetzel fixed-effect
model, with 95% confidence intervals. This meta-analysis
was not part of the original study protocol.
Ethics approval
The trial was conducted in compliance with the study
protocol [13], the principles of Good Clinical Practice,
the NHMRC National Statement on Ethical Conduct in
Human Research (2007), NHMRC Australian Code for the
Responsible Conduct of Research (2007), and NHMRC
Values And Ethics: Guidelines For Ethical Conduct InAboriginal And Torres Strait Islander Health Research
(2003) [23-25]. The trial received approval from The
University of Western Australia Human Research Ethics
Committee and the Western Australian Aboriginal Health
Information and Ethics Committee, and support from the
Kimberley Aboriginal Health Planning Forum Kimberley
Research Subcommittee.
Results
Participant recruitment occurred from January 2009 to
May 2011 and follow-up occurred from February 2010
to July 2012. Common reasons that potential partici-
pants were unwilling to consent were a lack of willing-
ness to be involved in a research project or not being
interested in quitting smoking. Of the 168 participants
who were randomised to the study, 163 continued in the
study (Figure 1) and their baseline characteristics, and
smoking and related risk behaviours were generally
similar between the intervention and usual care groups
(Tables 1 and 2). The small difference in mean age
(38.3 v 41.9 years) between the intervention and usual
care group was statistically but not clinically significant.
Participants in both groups reported high levels of alcohol,
cannabis and other illicit drug use (Table 2).
An average of 7 of the 12 planned formal smoking
cessation sessions were provided by the Aboriginal
researchers to participants in the intervention group.
Additional informal contact occurred throughout the
study period (e.g. Aboriginal researchers meeting parti-
cipants while out in the community and stopping to
discuss how they are going with their quit smoking
attempt). Twenty two (40%) participants in the interven-
tion group had documented action plans. In addition to
the content delivered by Aboriginal researchers during
smoking cessation counselling sessions (see Methods),
they also provided service mapping and linkages to other
services. Individual case conferences with clinic staff did
not happen as frequently as planned and only occurred
as required. Few participants attended group sessions.
Clinic staff were reported to have provided the same
level of routine care relating to smoking cessation to both
groups: 23% of participants reported that they spoke to
clinic staff about smoking during the study. Overall partic-
ipants reported that clinic staff provided advice on risks of
smoking (75%), recommended quitting smoking (71%),
recommended medication to assist with quitting (54%),
discussed passive smoking (61%), provided practical advice
on quitting (50%), provided written advice on quitting
(46%), arranged for a follow-up appointment (46%), and
set a quit date (32%). There was no difference between
groups. Participants were predominantly offered NRT
Patches (39%) or varenicline (14%).
One hundred and forty-four (88%) participants were
followed-up after 12 months, with 92 (56%) providing
Randomised (n=168)
Allocated to Usual Care (n=110)
Assessed for inclusion (n=238)
Discontinued study (n=2) 
• Deceased (n=1)
• Withdrew consent (n=1)
Allocated to Intervention (n=58)
Analysed 6 months (n=64/108)
• Temporary lost to follow up (n=39)
• Permanent lost to follow up (n=5)
Discontinued study (n=3)
• Deceased (n=3)
• Withdrew consent (n=0)
Analysed 6 months (n=33/55)
• Temporary lost to follow up (n=17)
• Permanent lost to follow up (n=5)
Analysed 12 months (n=95/108)
• Lost to follow-up (n=13)
Analysed 12 months (n=49/55)
• Lost to follow-up (n=6)
Not meeting inclusion criteria (n=70) 
• Non Indigenous (n=4)
• Unable to consent (n=1)
• Unwilling to consent (n=65)
Figure 1 CONSORT flow of participants through study.
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to follow-up was due to participants moving home and
Aboriginal researchers not knowing where they moved
to so they were unable to contact them.
For four participants there was a discrepancy between
self-report smoking status and cotinine levels. Thirteen
participants reported quitting smoking and 13 had a
cotinine level consistent with not smoking. Two smokers
(usual care group) claimed they had quit smoking at theTable 1 Baseline characteristics of participants assigned to us
Characteristic
Age
Female
Location
Ord Valley Aboriginal Health Service
Derby Aboriginal Health Service
Socioeconomic
Current employment
Formal education (year 10 or higher)
Long-term health conditions†
Self-reported health as fair/poor
Self-reported major event(s) that affected their smoking in the past 12 month
Data are number (%) or mean (standard deviation).
* P <0.05.
†Includes: high blood pressure; diabetes; kidney disease; eye problems not fixed by
or hearing problems; mental health problems; cancer.
‡Includes: death of family member or close friend, splitting up with partner, being ifinal follow-up, however both reported quitting within
the last 24 hours and had high cotinine levels. Two
participants (intervention group) who self-reported
continuing smoking had cotinine levels consistent with
not smoking (below the level of detection of 20 ng/mL).
One of these participants had the urine sample collected
three months after the final questionnaire was admi-
nistered and reported not smoking at the time of urine
collection, no reason was identified for the otherual care and intervention groups
Usual care group (n = 108) Intervention group (n = 55)
38.3 (12.0) 41.9 (11.9)*
54/108 (50%) 35/55 (64%)
67/108 (62%) 35/55 (64%)
41/108 (38%) 20/55 (36%)
51/102 (50%) 30/53 (57%)
76/102 (74%) 35/51 (68%)
66/104 (63%) 35/52 (67%)
30/106 (28%) 13/54 (24%)
s‡ 47/100 (47%) 20/51 (39%)
glasses; heart disease; chest/lung problems, including asthma, emphysema; ear
n prison or a family member in prison.
Table 2 Baseline smoking and related risk behaviours of participants assigned to usual care and intervention groups
Characteristic Usual care group (n = 108) Intervention group (n = 55)
Smoking*
Average number of cigarettes smoked per day 15 (10–25) 15 (11–25)
Years since started smoking 19.0 (10.9–26.7) 24.2 (15.0–31.6)
Age first started smoking 16 (14–18) 17 (15–19)
Nicotine dependency score ≤5 [26] 49/102 (48%) 24/53 (45%)
Self-reported desire to quit 63/105 (60%) 28/53 (53%)
Other drug use
Current alcohol drinker 77/105 (73%) 41/53 (77%)
Smoked marijuana within the last month 37/105 (35%) 14/52 (27%)
Ever used other illicit drugs 17/104 (16%) 8/53 (15%)
Data are number (%) or median (interquartile range).
*Missing data for average number of cigarettes smoked per day: 4 usual care and 6 intervention; years since started smoking: 4 usual care and 2 intervention; age
first started smoking: 4 usual care and 2 intervention.
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smoking. As participants were only classified as not
smoking if they satisfied both criteria, these four
participants were classified as still smoking at final
follow-up.
Participants in the intervention group quit smoking
sooner than those in the usual care group: all interven-
tion group participants reported quitting at least two
months before the final follow-up, as against only three
of five in the usual care group. There was no difference
in the median time between enrolling and final follow-
up for both groups (13 (IQR 12–15) months).
The proportions quitting smoking at final follow-up
are shown in Table 3. Based on cotinine results alone at
final follow-up the intervention group had a significantly
higher proportion who quit smoking than the usual care
group. However, based on the combination of self-report
and cotinine level at final follow-up, the final results
(2.4; 95% CI, 0.8-7.4, p = 0.131) were not statistically
significant. A meta-analysis of the BOABS Study and the
only other published RCT of a personal support interven-
tion with validated smoking cessation [8] demonstrated a
statistically significant higher smoking cessation rate
for participants in intervention compared to usual
care groups (Figure 2).Table 3 Number of BOABS Study participants who had stopp
Outcome Us
Urinary cotinine <50 ng/mL
Self-report quitting and urinary cotinine <50 ng/mL for participants
with complete outcome data
Self-report quitting and urinary cotinine <50 ng/mL assuming those
lost to follow-up were still smoking
Data are number (%) based on the study arm to which participants were originally
*Fishers exact;
†Compared with usual care group;No-one who had been recently incarcerated, chewed
tobacco, or drank alcohol daily quit smoking. Age and
gender were not independently associated with quitting.
There was no relationship between the easily quantifi-
able measures of the intervention (documented action
plan, or plan to stop smoking, setting a quit date and
number of smoking cessation counselling sessions) and
success in stopping smoking at final follow-up. We
could not measure the quality of the relationships
between the researchers and participants, which was
likely to be important.
Secondary endpoints are summarised in Table 4.
Follow-up at six months was only 59% (Figure 1) with
seven of the 64 (11%) and three of the 33 (9%) partici-
pants in the usual care and intervention groups, respect-
ively, self-reporting quitting smoking at six months. This
was not validated with urinary cotinine.
Discussion
The current study did not demonstrate a statistically
significant benefit from the BOABS intervention and
due to difficulties recruiting participants did not have
the power to do so. Pooling our data in a meta-analysis
of the only other reported Indigenous smoking cessation
RCT using a personal support intervention and validateded smoking at final follow-up
ual care group Intervention group P* RR (95% CI)†
5/64 (8%) 8/28 (29%) 0.009 3.7 (1.3–10.2)
5/95 (5%) 6/49 (12%) 0.135 2.3 (0.7–7.2)
5/108 (5%) 6/55 (11%) 0.131 2.4 (0.8–7.4)
assigned;
Overall  (I-squared = 0.0%, p = 0.886)
Eades
BOABS
Study
2009
2012
Year
11/148
6/55
Intervention
4/115
5/108
Usual
care
2.36 (1.01, 5.53)
2.23 (0.69, 7.19)
2.52 (0.73, 8.67)
OR (95% CI)
100.00
52.62
47.38
%
Weight
Usual care  Intervention 1.1 10
Heterogeneity: Chi2= 0.02, df = 1 (P= 0.89), I2= 0.0%
Test for overall effect: Z =  1.98 (P= 0.047)
Figure 2 Comparison of smoking cessation for ‘usual care’ versus ‘intervention’ of randomised controlled trials involving Indigenous
people*. * Smoking cessation was verified by cotinine, assuming those lost to follow-up were still smoking.
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cant increase in quitting (OR 2.4, 95% CI 1.01-5.5). This
is similar to smoking cessation interventions in non-
Indigenous settings (OR 1.4-2.2) [5]. Doubling the quit
rate is a clinically important improvement and based on
these pooled data one-on-one intensive interventions
delivered by, and provided to, Indigenous Australians
through a primary healthcare setting are more effective
than usual care in encouraging people to stop smoking.
Both studies while more intensive than usual care were
less intensive than originally planned. The participants
in the BOABS intervention group received an average of
seven of 12 smoking cessation sessions over 12 months
and 40% had documented action plans for helping them
to quit smoking. In contrast only 23% of participants in
the usual care group reported discussing smoking cessa-
tion with clinic staff. In the non-Indigenous setting a
systematic review of physician advice found increasing
the intensity of the intervention showed a small advan-
tage over minimal advice (RR 1.37; 95% CI 1.2-1.6) [27].
The level of intensity in these studies varied from brief
intervention to repeated advice to quit as an inpatient
with follow up in a special clinic.
Increasing the intensity of the intervention may have
had an impact on the quit rate in the intervention
groups of both the Eades study and BOABS. Although
the Australian Indigenous smoking prevalence is high,Table 4 Secondary endpoints of BOABS Study participants
Self-reported health as fair/poor
Nicotine dependency score ≤5 [26]†
Baseline
Final follow-up
Reduced average daily cigarettes by ≥20%
Attempted to quit at any time during the study
Data are number (%) based on the study arm to which participants were originally
†Only included participants who had a nicotine dependency score recorded at basethere was only a 3% quit rate in a local program deliv-
ered at one of the sites prior to the BOABS intervention
(personal communication CN). The quality of the rela-
tionships between the BOABS Aboriginal researchers
and participants may well have had an impact. A qualita-
tive evaluation of the observations and notes from the
BOABS Study is required to further elucidate this.
There was repeated clinic and research staff training
about roles and responsibilities to minimise contamin-
ation between groups. The process of regular follow up,
the core of the intervention, appeared to be relatively
free from contamination. Nonetheless even if some
contamination did occur it was likely to reduce the dif-
ference between the intervention and usual care groups.
A limitation of both this study and the study by Eades
and others was the lower than expected numbers of
participants and an attendant lack of statistical power.
While the BOABS Study had a high follow-up rate for a
relatively long-term community-based RCT (88% actual
follow-up v 90% planned), we were unable to recruit the
planned number of participants. In this study there were
a number of reasons why people chose not to enrol even
though they wanted assistance to help quit smoking and
most of these related to the consent and/or the random-
isation processes. Therefore, we believe that more people
will be interested in joining a program than a research
study. It is unclear whether the people who did not wantUsual care group Intervention group
21/94 (22%) 14/49 (29%)
26/50 (52%) 11/27 (41%)
34/50 (68%) 18/27 (67%)
38/74 (51%) 15/35 (43%)
36/90 (40%) 27/48 (56%)
assigned;
line and final follow-up.
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quit than those who did participate.
Despite more than doubling the time for recruitment
only about half of the expected number of participants
were recruited. While we have demonstrated it is possible
to undertake high quality RCTs in Aboriginal primary
health care settings [28] the difficulty of enrolling partici-
pants in future studies should not be underestimated and
needs to be carefully considered in planning.
Solutions to the problems of insufficient numbers and
contamination include using more sites in multicentre
trials and randomising at the cluster level. Individually
randomised multicentre drug trials have been demon-
strated to be possible in Aboriginal and Torres Strait
Islander health [28]. Cluster randomised multicentre
trials may be another solution for more complex non-
placebo controllable interventions such as BOABS,
however the risks of: 1) heterogeneity between sites; 2)
the intervention only working in some locations; 3)
added complexity of both design and analysis; 4) a sub-
stantially larger sample size required to obtain the same
statistical power; 5) post-randomisation selection bias if
randomisation occurs prior to participant recruitment;
and 6) a potential slowdown of recruitment in the clus-
ters that are to receive the less interesting treatment
such as “usual care” [29-31], remain.
In addition to the risks listed above, RCTs are not well
placed to take into account the need for operational
changes of health service providers to deliver an inter-
vention such as BOABS [30]. In the BOABS Study,
because it was an RCT and by definition could not be
delivered as part of usual health care, the intervention
was delivered by individual workers and by design was
not intended to create substantial change to the actions
of other health care staff or the day to day operation of
the clinics. We believe this had a negative effect on both
recruitment and the intervention.
Although RCTs are generally considered the gold
standard in research, it has been argued that in complex
public health interventions other methodologies should
be pursued [30]. Similarly RCTs may not be the best
design for complex clinical individualised interventions
such as BOABS. Alternative methodologies include plausi-
bility (observational design with a comparison group) and
adequacy (process indicators and outcome data are
used to suggest if the intervention is having an im-
portant effect) evaluations [30]. While these method-
ologies provide lower levels of evidence, recruitment
would be expected to be higher as it is not restricted
in the same way it is in RCTs, and they should have
greater potential to be generalisable. Future and ongoing
evaluation of smoking cessation programs in this setting
should therefore consider other methodologies beyond
that of RCTs.Conclusion
Whilst the BOABS study did not demonstrate a signifi-
cant benefit from a multi-dimensional smoking cessation
intervention the meta-analysis of our and Eades’ earlier
study does demonstrate that one-on-one intensive inter-
vention delivered by and provided to Aboriginal and
Torres Strait Islander peoples in a primary healthcare
setting is more effective than usual care in encouraging
smoking cessation. Taking into account the feasibility
and cost-effectiveness of RCTs and cluster randomised
trials, the priority should be to demonstrate the effect-
iveness of programs based on personal support to quit
smoking in a real world setting. The questions should be
whether real world interventions work in practice,
whether they are cost effective and sustainable and to
identify enablers and barriers to the integration of such
programs into primary health care for Aboriginal and
Torres Strait Islander peoples.
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